| 摘要 |
The invention is directed to physiologically active compounds of general formula (I): wherein: R<1 >represents aryl, heteroaryl or a group R<3>-L<2>-Ar<1>-L<3>-; R<2 >represents hydrogen or lower alkyl; R<3 >represents aryl or heteroaryl; and Ar<1 >represents an optionally substituted saturated, partially saturated or fully unsaturated 8 to 10 membered bicyclic ring system containing at least one heteroatom selected from O, S or N; Y is carboxy or an acid bioisostere; and their corresponding N-oxides or prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their corresponding N-oxides or prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (alpha4beta1).
|
